LU88811I2 - Liposome daunorubicine optionellement sous forme d'un sel d'addition acide les liposomes comprenant un phospholipide chimiquement pur (pureté>98%) et de zéro à cinquante pourcents en poids de cholestérol par rapport au phospholipide et les liposomes ayant une taille inférieure à 200nm - Google Patents

Liposome daunorubicine optionellement sous forme d'un sel d'addition acide les liposomes comprenant un phospholipide chimiquement pur (pureté>98%) et de zéro à cinquante pourcents en poids de cholestérol par rapport au phospholipide et les liposomes ayant une taille inférieure à 200nm

Info

Publication number
LU88811I2
LU88811I2 LU88811C LU88811C LU88811I2 LU 88811 I2 LU88811 I2 LU 88811I2 LU 88811 C LU88811 C LU 88811C LU 88811 C LU88811 C LU 88811C LU 88811 I2 LU88811 I2 LU 88811I2
Authority
LU
Luxembourg
Prior art keywords
liposomes
phospholipid
purity
zero
micellular
Prior art date
Application number
LU88811C
Other languages
English (en)
Original Assignee
Nexstar Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US06/663,550 external-priority patent/US5441745A/en
Priority claimed from US06/663,503 external-priority patent/US5435989A/en
Application filed by Nexstar Pharmaceuticals Inc filed Critical Nexstar Pharmaceuticals Inc
Publication of LU88811I2 publication Critical patent/LU88811I2/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
    • A61K51/1217—Dispersions, suspensions, colloids, emulsions, e.g. perfluorinated emulsion, sols
    • A61K51/1234—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Dispersion Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
LU88811C 1984-10-22 1985-10-22 Liposome daunorubicine optionellement sous forme d'un sel d'addition acide les liposomes comprenant un phospholipide chimiquement pur (pureté>98%) et de zéro à cinquante pourcents en poids de cholestérol par rapport au phospholipide et les liposomes ayant une taille inférieure à 200nm LU88811I2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US06/663,550 US5441745A (en) 1982-03-30 1984-10-22 Method of delivering micellular particles encapsulating chemotherapeutic agents to tumors in a body
US06/663,503 US5435989A (en) 1982-03-30 1984-10-22 Method of targeting a specific location in a body

Publications (1)

Publication Number Publication Date
LU88811I2 true LU88811I2 (fr) 1996-11-05

Family

ID=27098764

Family Applications (1)

Application Number Title Priority Date Filing Date
LU88811C LU88811I2 (fr) 1984-10-22 1985-10-22 Liposome daunorubicine optionellement sous forme d'un sel d'addition acide les liposomes comprenant un phospholipide chimiquement pur (pureté>98%) et de zéro à cinquante pourcents en poids de cholestérol par rapport au phospholipide et les liposomes ayant une taille inférieure à 200nm

Country Status (11)

Country Link
EP (1) EP0179444B1 (fr)
JP (1) JPH0747533B2 (fr)
KR (1) KR900004802B1 (fr)
AT (1) ATE64298T1 (fr)
CA (1) CA1298548C (fr)
DE (2) DE19675031I2 (fr)
DK (2) DK482685D0 (fr)
HK (1) HK119993A (fr)
IE (1) IE58659B1 (fr)
LU (1) LU88811I2 (fr)
NL (1) NL960020I1 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE60901B1 (en) * 1986-08-21 1994-08-24 Vestar Inc Improved treatment of systemic fungal infections with phospholipid particles encapsulating polyene antifungal antibiotics
US5043107A (en) * 1986-08-21 1991-08-27 Vestar Research, Inc. Preparation small unilamellar vesicles including polyene antifungal antibiotics
IL88076A (en) * 1987-10-28 1993-01-14 Nippon Shinyaku Co Ltd Fat emulsions as drug carriers
AU598958B2 (en) * 1987-11-12 1990-07-05 Vestar, Inc. Improved amphotericin b liposome preparation
US5648532A (en) * 1993-06-03 1997-07-15 The Regents Of The University Of California Compositions for boron neutron capture therapy and methods thereof
DE19606326A1 (de) * 1995-02-09 1996-08-22 Schering Ag Kontrastmittelhaltige Liposomenformulierung sowie deren Verwendung für die In-vivo-Diagnostik, insbesondere für die Darstellung des Intravasalraumes
NO312708B1 (no) * 2000-02-21 2002-06-24 Anticancer Therapeutic Inv Sa Radioaktive liposomer til terapi
JP2007512221A (ja) * 2003-11-21 2007-05-17 富士フイルム株式会社 疎水性キレート化合物を含有するリポソームを含む造影剤
EP1745788A1 (fr) * 2005-07-22 2007-01-24 KTB Tumorforschungsgesellschaft mbH Acylglycerophospholipides pour le traitement du cancer et de la cachexie
JP5936002B2 (ja) * 2010-11-19 2016-06-15 北海道公立大学法人 札幌医科大学 組合わせ医薬製剤

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4310505A (en) * 1979-11-08 1982-01-12 California Institute Of Technology Lipid vesicles bearing carbohydrate surfaces as lymphatic directed vehicles for therapeutic and diagnostic substances
JPS59122423A (ja) * 1982-12-28 1984-07-14 Green Cross Corp:The 制癌剤含有脂肪乳剤
JPS59163315A (ja) * 1983-03-09 1984-09-14 Mitsui Pharmaceut Inc カルモフ−ル含有リポソ−ム

Also Published As

Publication number Publication date
KR900004802B1 (ko) 1990-07-06
JPS61158932A (ja) 1986-07-18
DK482685D0 (da) 1985-10-21
EP0179444A3 (en) 1987-08-12
EP0179444A2 (fr) 1986-04-30
KR860003514A (ko) 1986-05-26
JPH0747533B2 (ja) 1995-05-24
EP0179444B1 (fr) 1991-06-12
CA1298548C (fr) 1992-04-07
DK484585A (da) 1986-04-23
DK167556B1 (da) 1993-11-22
DE19675031I2 (de) 2008-04-10
IE58659B1 (en) 1993-11-03
DK484585D0 (da) 1985-10-22
IE852602L (en) 1986-04-22
ATE64298T1 (de) 1991-06-15
NL960020I1 (nl) 1996-11-01
HK119993A (en) 1993-11-12
DE3583204D1 (de) 1991-07-18

Similar Documents

Publication Publication Date Title
US5631394A (en) Pharmaceutically active ceramide-related compounds
US5344930A (en) Fluorine and phosphorous-containing amphiphilic molecules with surfactant properties
DE69232101T2 (de) Lipid-derivate von phosphonsäuren für liposomale inkorporation und verwendungsverfahren
Johnson et al. Catalytic properties of phospholipid exchange protein from bovine heart
DE69637381T2 (de) Prodrugs von pharmazeutika mit erhöhter bioverfügbarheit
LU88811I2 (fr) Liposome daunorubicine optionellement sous forme d'un sel d'addition acide les liposomes comprenant un phospholipide chimiquement pur (pureté>98%) et de zéro à cinquante pourcents en poids de cholestérol par rapport au phospholipide et les liposomes ayant une taille inférieure à 200nm
AU587232B2 (en) Anthracycline antineoplastic agents encapsulated in phospholipid micellular particles and methods for using same for tumor therapy
EP0280492A2 (fr) Composition pour liposome et sa préparation
Lundberg Preparation of drug-low density lipoprotein complexes for delivery of antitumoral drugs via the low density lipoprotein pathway
Rye et al. Changes in the size and density of human high-density lipoproteins promoted by a plasma-conversion factor
EP0198388A3 (fr) Composition biologique à activité entérique à base de peptides ou de protéines, son procédé de fabrication et composition pharmaceutique la contenant
AU3967689A (en) Lipid derivatives of antiviral nucleosides, liposomal incorporation and method of use
DE3472406D1 (en) Pharmaceutical compositions and method for preparing phosphatidylserine compositions useful in treating central nervous system disorders without effects on blood coagulation
Riess Introducing a new element-fluorine-into the liposomal membrane
CA2299429A1 (fr) Nouvelles lipopolyamines, leurs methodes de preparation, et utilisations connexes
KR100243933B1 (ko) 과량의 음전하를 지니는 리포솜
EP0122813B1 (fr) Complexes du technétium-99m pour le diagnostic des os
US6017557A (en) Carriers containing an etherlipid/complementarily shape lipid combination and therapeutic uses thereof
Helmkamp Jr Interaction of bovine brain phospholipid exchange protein with liposomes of different lipid composition
Robinson et al. Comparison of albumin-mediated release of lysophosphatidylcholine and lysophosphatidylethanolamine from cultured rat hepatocytes
Wu et al. Targeted delivery and expression of foreign genes in hepatocytes
Snyder et al. Uptake of the 35 kDa major surfactant apoprotein (SP-A) by neonatal rabbit lung tissue
ATE70456T1 (de) Verwendung von micellaren partikeln zur herstellung von zusammensetzungen zum beschiessen von tumoren in menschen und deren verwendung.
El Battari et al. Modification of HT 29 cell response to the vasoactive intestinal peptide (VIP) by membrane fluidization
YAGUCHI et al. Effect of sulfatide-inserted liposomes containing entrapped adriamycin on metastasized cells in lymph nodes